Simplifying treatment and reducing recurrence for patients with early-stage bladder cancer
Mené sur 383 patients avec suspicion de cancer non invasif de faible grade de la vessie (âge médian : 66 ans ; 84,7% d'hommes), cet essai multicentrique évalue, du point de vue du délai avant récidive, l'efficacité d'une instillation intravésiculaire de gemcitabine une heure après une résection transurétrale de la tumeur
The burden of bladder cancer in the United States is large and expanding with the aging population; the annual incidence has increased from approximately 50 000 cases per year in the 1990s1 to nearly 80 000 new cases projected for 2017.2 Non–muscle-invasive bladder cancers represent approximately 75% of all incident cases,3 of which the majority are low-grade tumors. Low-grade bladder cancers frequently recur but rarely result in cancer progression or death. In addition to being the most expensive cancer per patient,4 bladder cancer disproportionately affects older patients, with a median age at diagnosis of 73 years, the oldest age at diagnosis of all cancer sites.5 Thus, patients with low-grade bladder cancer often live with this diagnosis as one of multiple chronic conditions.6
JAMA , éditorial, 2017